The Alzheimer's Association® will present 10 scientific awards at the Alzheimer's Association International Conference® 2025 (AAIC®), recognizing researchers for their expertise, noteworthy ...

Key Takeaways At AAIC 2025, the Alzheimer's Association released the first in a series of clinical practice guidelines for the diagnosis, treatment and care of Alzheimer's and all other ...

Researchers say the repurposed drugs could accelerate a long-stalled path toward meaningful Alzheimer’s treatment. (Scripps News) ...

Although it's not always easy to determine if an individual can make decisions, a judge understands the obvious that a ...

Microglia, a type of brain immune cell, can gobble up amyloid beta protein, which clumps together into toxic aggregates ...

Scientists at UCSF have uncovered how certain immune cells in the brain, called microglia, can effectively digest toxic ...

ALZpath’s pTau217 antibody is drawing significant attention at this year’s Alzheimer's Association International Conference (AAIC), taking place in Toronto, Canada, from 27-31 July. The biomarker ...

In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months of treatment, representing what B. Riley Securities called a “paradigm shift ...

The Columbus Alzheimer’s/Dementia Support Group will meet at 1:30 p.m. Monday, July 28, at the Columbus Senior Center (old ...

Presentation to highlight the Company's proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310 Posters highlighting PRECISE-AD, the Company's Phase 1b clinical trial design and ...

In Alzheimer's disease, proteins like amyloid beta form clumps, known as plaques, that damage the brain.But in some people, ...

A new drug cleared 91% of brain amyloid plaques in 7 months, showing faster results than current Alzheimer's treatments and advancing to Phase III trials in 2025.